FPR Agonist 43 is primarily utilized in research settings to study the role of formyl peptide receptors (FPRs) in various physiological and pathological processes. It is commonly employed in immunology and inflammation studies to investigate how FPR activation influences immune cell behavior, such as chemotaxis, phagocytosis, and the release of inflammatory mediators. This compound is also used in cancer research to explore its potential effects on tumor-associated macrophages and its role in modulating the tumor microenvironment. Additionally, FPR Agonist 43 aids in understanding neurodegenerative diseases by examining its impact on neuroinflammation and neuronal survival. Its application extends to drug discovery, where it serves as a tool to identify and validate novel therapeutic targets related to FPR signaling pathways.